tickdelta
Sign in

Tickdelta is free for now. Sign up and get Pro free

← Screener

VTRSViatris

Health care · Pharmaceuticals · Nasdaq

Viatris is a global healthcare company whose breadth and scale we believe make it uniquely positioned to address healthcare needs globally. 10-K, Item 1

Headquarters
Canonsburg, PA
CEO
Scott A. Smith
Next results
around Feb 25, 2027
Compare with peers → Embed

The biggest changes in the 10-K filed 2026-02-26, this fiscal year against the last, and the sentences in the MD&A (Item 7) where management explains them, quoted word for word. Tickdelta picks sentences that name the line, a direction and a cause. It does not write explanations of its own.

Operating margin

0.1% → -18.7% (-18.8 pts) Big change FY to 2025-12-31 vs 2024-12-31

The MD&A has no sentence that names a cause for this change. That can be worth a question: ask about the filing.

Gross margin

38.3% → 35.2% (-3.1 pts) Big change FY to 2025-12-31 vs 2024-12-31

“The increase in cost of sales was largely driven by higher costs associated with other special items, which are described further in the section titled Use of Non-GAAP Financial Measures, and by product mix as a result of the Indore Impact.”

Read it in the 10-K ↗

“The changes in gross profit and gross margins are primarily related to the increase in cost of sales.”

Read it in the 10-K ↗

Revenue

-3.0% FY to 2025-12-31 vs 2024-12-31

“On a constant currency basis, net sales from the remaining business decreased by approximately $142.1 million, or 1%, for the year ended December 31, 2025 compared to the prior year period, driven by net base business erosion of approximately $465.8 million, of which approximately $370 million related to the Indore Impact.”

Read it in the 10-K ↗

“Constant currency net sales from the remaining business decreased by approximately $255.9 million, or 3%, driven primarily by lower net sales of certain existing products, including lenalidomide and everolimus in the U.S., as a result of the Indore Impact of approximately $283 million, partially offset by new product sales.”

Read it in the 10-K ↗

Cash from operations

+0.6% FY to 2025-12-31 vs 2024-12-31

The MD&A has no sentence that names a cause for this change. That can be worth a question: ask about the filing.

Changes are computed from the XBRL figures in the same 10-K. Hover a number to see the line item. Open the 10-K ↗

Work on VTRS in a spreadsheet: Excel workbook (a sheet per section, ten years by column, charts, links to the filings) · CSV. For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/VTRS/export.csv") into a cell.